Document Detail


Guidelines for the use of corticosteroids in the treatment of pulmonary sarcoidosis.
MedLine Citation:
PMID:  17521216     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Sarcoidosis is the most common diffuse parenchymal lung disease and occurs worldwide. Although it affects all ethnic groups, prevalence and severity varies between different races. This has complicated the interpretation of existing clinical studies and extrapolation of their findings to different populations. Sarcoidosis can affect any organ, but the lungs are involved in >90% of patients, and respiratory specialists are therefore frequently responsible for their care. Oral corticosteroids have been used to treat sarcoidosis since the 1950s, with evidence of short- to medium-term improvement in symptoms, respiratory function and radiology. More recently, there have been studies examining the role of inhaled corticosteroids. The long-term benefits of corticosteroid treatment are nevertheless uncertain. Current international guidelines (published in 1999) on sarcoidosis, including recommendations on treatment, represent a consensus statement endorsed by North American and European respiratory societies. British guidelines on diffuse parenchymal lung disease, including sarcoidosis, were published in the same year. There are clearly areas where there is agreement and others where uncertainty persists. This article outlines current guidance with particular reference to which patients should be treated, when treatment should be commenced, the possible role of inhaled corticosteroids, how long treatment should be continued, and what monitoring should be performed for adverse events.
Authors:
Robina K Coker
Related Documents :
12835566 - Effect of high-dose intravenous immunoglobulin therapy in stevens-johnson syndrome: a r...
8978966 - Vasculitis in systemic lupus erythematosus following intravenous immunoglobulin therapy.
2491766 - Fetal lung maturation: the combined use of corticosteroids and thyrotropin-releasing ho...
16125506 - Management, risk factors, and outcomes in recurrent pericarditis.
18260486 - Arthroscopic ankle debridement: 5-year survival analysis.
18634956 - Neuro-reflexotherapy for the management of myofascial temporomandibular joint pain: a d...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  67     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2007  
Date Detail:
Created Date:  2007-05-24     Completed Date:  2007-08-10     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  1139-47     Citation Subset:  IM    
Affiliation:
Respiratory Medicine, Hammersmith Hospitals NHS Trust, London, England. robina.coker@imperial.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Administration, Oral
Glucocorticoids / administration & dosage,  adverse effects,  therapeutic use*
Humans
Practice Guidelines as Topic*
Sarcoidosis, Pulmonary / drug therapy*
Chemical
Reg. No./Substance:
0/Glucocorticoids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Epidermal growth factor receptor inhibitors in non-small cell lung cancer.
Next Document:  Management options for malignant pleural mesothelioma: clinical and cost considerations.